Patents Assigned to Molecular Diagnostics, Inc.
-
Patent number: 11384399Abstract: Described herein are innovations for classifying subtypes of DLBCL, as well as using the results of classification for diagnosis, prognosis, and therapy selection. In this way, the classifier can effectively classify subtypes of DLBCL and provide meaningful output for the benefit of medical practices and DLBCL patients. Also described are arrays and kits that can be used to measure expression of DLBCL signatures genes.Type: GrantFiled: September 29, 2016Date of Patent: July 12, 2022Assignee: HTG Molecular Diagnostics, Inc.Inventors: Bonnie LaFleur, Qian Liu, John W. Luecke, Patrick C. Roche
-
Publication number: 20220106640Abstract: The present disclosure provides methods for sequencing nucleic acid targets (e.g., both DNA and RNA co-amplified in a sample mixture, for example by using a surrogate for the RNA). Such methods can be used to determine if one or more nucleic acid targets are present in a sample.Type: ApplicationFiled: December 2, 2019Publication date: April 7, 2022Applicant: HTG Molecular Diagnostics, Inc.Inventors: Debrah Thompson, Matthew Rounseville
-
Patent number: 11274351Abstract: Compositions, reactions mixtures, kits, and systems for detecting bacterial contamination are provided, as well as methods of using the same.Type: GrantFiled: July 2, 2019Date of Patent: March 15, 2022Assignee: DCH MOLECULAR DIAGNOSTICS, INC.Inventors: James Jian Quan Wang, Xiangmin Cui, Wayne Jer Hsieh, HiuNam Chan
-
Patent number: 11268133Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.Type: GrantFiled: April 8, 2019Date of Patent: March 8, 2022Assignee: HTG Molecular Diagnostics, Inc.Inventors: Bruce A. Seligmann, BJ Kerns, John Luecke, Matt Rounseville, Ihab Botros, Mark Schwartz
-
Patent number: 10392670Abstract: Compositions, reactions mixtures, kits, and systems for detecting bacterial contamination are provided, as well as methods of using the same.Type: GrantFiled: July 23, 2014Date of Patent: August 27, 2019Assignee: DCH MOLECULAR DIAGNOSTICS, INC.Inventors: James Jian Quan Wang, Xiangmin Cui, HiuNam Chan
-
Publication number: 20190226013Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.Type: ApplicationFiled: April 8, 2019Publication date: July 25, 2019Applicant: HTG Molecular Diagnostics, Inc.Inventors: Bruce A. Seligmann, BJ Kerns, John Luecke, Matt Rounseville, Ihab Botros, Mark Schwartz
-
Patent number: 10294515Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes, and detecting the fusion probe after nuclease treatment. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes, and detecting these probes after nuclease treatment. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.Type: GrantFiled: December 7, 2011Date of Patent: May 21, 2019Assignee: HTG Molecular Diagnostics, Inc.Inventors: Bruce Seligmann, BJ Kerns, John Luecke, Matt Rounseville, Ihab Botros, Mark Schwartz
-
Publication number: 20190017112Abstract: The present disclosure provides methods and kits for direct sequencing of nucleic acid targets. Such methods can be used to determine if one or more nucleic acid targets are present in a sample.Type: ApplicationFiled: February 10, 2017Publication date: January 17, 2019Applicant: HTG Molecular Diagnostics, Inc.Inventors: Debrah Thompson, Matthew Rounseville
-
Publication number: 20180340231Abstract: Described herein are innovations for classifying subtypes of DLBCL, as well as using the results of classification for diagnosis, prognosis, and therapy selection. In this way, the classifier can effectively classify subtypes of DLBCL and provide meaningful output for the benefit of medical practices and DLBCL patients. Also described are arrays and kits that can be used to measure expression of DLBCL signatures genes.Type: ApplicationFiled: September 29, 2016Publication date: November 29, 2018Applicant: HTG Molecular Diagnostics, Inc.Inventors: Bonnie LaFleur, Qian Liu, John W. Luecke, Patrick C. Roche
-
Patent number: 9765385Abstract: Disclosed herein are methods for detecting presence of a nucleotide variant in a target nucleic acid utilizing a nuclease protection assay. The methods include contacting a sample with at least two probes, wherein the first probe is complementary to the wild-type (non-variant) nucleotide(s) at the nucleotide variant position(s) in the target nucleic acid and the second probe is complementary to the variant nucleotide(s) at the nucleotide variant position(s) in the target nucleic acid, under conditions sufficient for the probes to hybridize to the target nucleic acid, producing a mixture of hybridized and unhybridized nucleic acids. The mixture is contacted with a nuclease specific for single-stranded nucleic acid molecules under conditions sufficient to remove unhybridized nucleic acid molecules (or unhybridized portions of nucleic acid molecules). The presence of the at least two probes is then detected, thereby detecting the presence of the variant and/or non-variant target nucleic acid in the sample.Type: GrantFiled: June 28, 2013Date of Patent: September 19, 2017Assignee: HTG Molecular Diagnostics, Inc.Inventors: Matt Rounseville, Bruce Seligmann
-
Patent number: 9758829Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.Type: GrantFiled: June 24, 2013Date of Patent: September 12, 2017Assignees: HTG Molecular Diagnostics, Inc., John Wayne Cancer InstituteInventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Tom Vasicek, B J Kerns, Bruce E. Seligmann, Dave S. B. Hoon
-
Patent number: 9512469Abstract: Disclosed herein are methods of co-detecting presence of target messenger RNA (mRNA) and small non-coding RNA (for example, miRNA) in a sample. The disclosed methods can be used to simultaneously detect mRNA and small non-coding RNA in a single assay (for example in the same reaction or the same well of a multi-well assay). The methods can include contacting a sample with a plurality of nuclease protection probes (NPPs) including at least one probe which specifically binds to a target mRNA and at least one probe which specifically binds to a target small non-coding RNA, contacting the sample with a nuclease specific for single-stranded nucleic acids, and detecting the NPP, for example on a microarray.Type: GrantFiled: September 26, 2012Date of Patent: December 6, 2016Assignee: HTG Molecular Diagnostics, Inc.Inventors: Bruce Seligmann, Matt Rounseville, Krishna Maddula, Ihab Botros, Chris Cox
-
Publication number: 20160019337Abstract: This disclosure concerns the identification of biomarkers that are characteristic of squamous or non squamous (e.g., adenocarcinoma, large cell carcinoma, carcinoid tumor, sarcomatoid carcinoma) subtypes of non small cell lung cancer (NSCLC), clinically useful NSCLC classifiers, kits and arrays for distinguishing squamous and nonsquamous NSCLC subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing.Type: ApplicationFiled: March 3, 2014Publication date: January 21, 2016Applicant: HTG Molecular Diagnostics, Inc.Inventors: Christopher Roberts, Hui Wang, Zhenquiang Lu, Krishna Maddula, Sam Rua, Kevin Knapp, Byron Lawson, Debrah Thompson, Michael Hrubiak, Tyler Breedlove, Vijay Modur
-
Publication number: 20150176072Abstract: Disclosed are methods for determining whether a melanocyte-containing sample (such as a nevus or other pigmented lesion) is benign or a primary melanoma. These methods can include detecting (at the molecular level, e.g., mRNA, miRNA, or protein) the expression of at least two disclosed genes in a biological sample obtained from a subject. Also provided are arrays and kits that can be used with the methods.Type: ApplicationFiled: June 24, 2013Publication date: June 25, 2015Applicants: HTG Molecular Diagnostics, INc., John Wayne Cancer InstituteInventors: Hui Wang, Christopher Roberts, Krishna Maddula, Zhenquiang Lu, Justin Brown, Tom Vasicek, BJ Kerns, Bruce E. Seligmann, Dave S.B. Hoon
-
Publication number: 20140235460Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.Type: ApplicationFiled: May 1, 2014Publication date: August 21, 2014Applicant: HTG Molecular Diagnostics, Inc.Inventors: Debrah Thompson, Bruce E. Seligmann, Debra A. Gordon
-
Patent number: 8741564Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.Type: GrantFiled: April 26, 2012Date of Patent: June 3, 2014Assignee: HTG Molecular Diagnostics, Inc.Inventors: Bruce Seligmann, Debrah Thompson, Tom Vasicek, Debra A. Gordon
-
Publication number: 20140120540Abstract: Disclosed herein are methods of detecting presence of a gene fusion in a sample from a subject. In some embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize a fusion probe that spans the point of fusion between two nucleic acids or genes, and detecting the fusion probe after nuclease treatment. In other embodiments, the methods of detecting presence of a fusion gene in a sample from a subject utilize two or more probes that flank the point of fusion between two nucleic acids or genes, and detecting these probes after nuclease treatment. In additional embodiments, the methods can include determining the percentage of gene fusion in the sample relative to the first nucleic acid or the second nucleic acid.Type: ApplicationFiled: December 7, 2011Publication date: May 1, 2014Applicant: HTG MOLECULAR DIAGNOSTICS, INC.Inventors: Bruce Seligmann, Bj Kerns, John Luecke, Matt Rounseville, Ihab Botros, Mark Schwartz
-
Publication number: 20140087954Abstract: The present disclosure provides an improvement to quantitative Nuclease Protection Assay (qNPA) and quantitative Nuclease Protection Sequencing (qNPS) methods. The disclosed methods use nuclease protection probes (NPPs) that include 5?-end and/or 3-end flanking sequences, which provide a universal hybridization and/or amplification sequence. The disclosed methods can be used to sequence or detect target nucleic acid molecules, such as those present in fixed or insoluble samples.Type: ApplicationFiled: April 26, 2012Publication date: March 27, 2014Applicant: HTG Molecular Diagnostics, Inc.Inventors: Bruce E. Seligmann, Debrah Thompson, Tom Vasicek, Debra A. Gordon
-
Patent number: 8624014Abstract: A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 1168 24mers is described.Type: GrantFiled: December 21, 2009Date of Patent: January 7, 2014Assignee: Luminex Molecular Diagnostics, Inc.Inventors: Daniel Kobler, Daniel Fieldhouse
-
Publication number: 20130288915Abstract: Disclosed herein are methods of predicting response of a tumor to an ALK inhibitor and methods of determining diagnosis or prognosis of a subject with a tumor. The methods can include detecting presence of an ALK gene fusion (such as EML4-ALK, TFG-ALK, or KIF5B-ALK) in a sample from a subject. Also disclosed herein are arrays for detecting the presence of ALK and/or ROS1 gene fusions in a sample. In some embodiments, the array includes one or more oligonucleotides complementary to an ALK or ROS1 gene fusion.Type: ApplicationFiled: April 3, 2013Publication date: October 31, 2013Applicant: HTG MOLECULAR DIAGNOSTICS, INC.Inventors: BRUCE E. SELIGMANN, BJ KERNS, MARK SCHWARTZ, JOHN W. LUECKE